Drug Combination Details
| General Information of the Combination (ID: C95896) | |||||
|---|---|---|---|---|---|
| Name | Cyclopamine NP Info | + | TNF-related apoptosis inducing ligand Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Stomach cancer
[ICD-11: 2B72]
|
Investigative | [1] | ||
|
Multiple myeloma
[ICD-11: 2A83]
|
Investigative | [2] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | Gli1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | SKO-007 | CVCL_4974 | Plasma cell myeloma | Homo sapiens | ||
| RPMI-8226 | CVCL_0014 | Plasma cell myeloma | Homo sapiens | |||
| Experimental
Result(s) |
Combination of cyclopamine and CPT exhibited Synergistic effects on the inhibition of proliferation and induction of apoptosis in myeloma cells. | |||||
| β. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | TRAIL-R2 | Molecule Info |
Pathway MAP
|
|
| Experimental
Result(s) |
Cyclopamine sensitizes TRAIL-resistant gastric cancer cells to TRAIL-induced apoptosis via endoplasmic reticulum stress-mediated increase of death receptor 5 and survivin degradation. | |||||
